Highlights

  • Morgan Stanley raises KYMR rating to Overweight, price target increased from USD49 to USD79
  • Shares currently trade at USD43.13; analyst targets range from USD38 to USD97
  • Company holds more cash than debt, with a current ratio of 8.49

On Tuesday, Morgan Stanley (NYSE:MS) upgraded Kymera Therapeutics (NASDAQ:KYMR) from Equalweight to Overweight, raising its price target to USD79 from USD49. The move reflects growing interest in the clinical progress of Kymera's drug pipeline, particularly its STAT6-targeting therapy KT-621.

At a current trading price of USD43.13, the updated price target suggests a potential 83.2% upside. Analyst targets for KYMR vary widely, ranging from USD38 to USD97, underscoring the high-risk, high-reward profile of clinical-stage biotech firms.

A key factor in the upgrade is Kymera’s KT-621, an oral STAT6 degrader being evaluated for inflammatory conditions like atopic dermatitis and asthma. Though still in early stages, the compound has shown over 90% STAT6 degradation at doses above 1.5 mg with no serious adverse events reported in Phase 1 trials. Morgan Stanley analysts cited the wide therapeutic window and safety profile as favorable indicators, particularly for dermatology applications.

Looking ahead, initial patient data for KT-621 is expected in Q4 2025, with Phase II trials targeted for early 2026. This timeline has contributed to broader analyst optimism: Truist Securities, Citi, BofA Securities, and Stifel have reaffirmed or raised Buy ratings in recent weeks. Citi’s price target now stands at USD60, while BofA has raised its target to USD51 following the latest Phase 1 results.

While development milestones remain ahead, investor attention is focused on how KT-621 progresses through upcoming trials and whether it can capture share in the growing market for inflammation and immunology therapies.